632.07
2.39 (0.38%)
| Penutupan Terdahulu | 629.68 |
| Buka | 630.38 |
| Jumlah Dagangan | 320,029 |
| Purata Dagangan (3B) | 726,109 |
| Modal Pasaran | 66,265,608,192 |
| Harga / Pendapatan (P/E TTM) | 15.44 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.24 |
| Harga / Jualan (P/S) | 4.61 |
| Harga / Buku (P/B) | 2.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2026 |
| Hasil Dividen (DY TTM) | 0.57% |
| Margin Keuntungan | 31.94% |
| Margin Operasi (TTM) | 19.94% |
| EPS Cair (TTM) | 39.36 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 12.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.20% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | 3.95 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.08 B |
| Pulangan Atas Aset (ROA TTM) | 6.91% |
| Pulangan Atas Ekuiti (ROE TTM) | 15.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Regeneron Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.13 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 1.89% |
| % Dimiliki oleh Institusi | 91.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 923.00 (Barclays, 46.03%) | Beli |
| Median | 844.00 (33.53%) | |
| Rendah | 765.00 (RBC Capital, 21.03%) | Pegang |
| Purata | 844.00 (33.53%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 775.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 06 Mar 2026 | 923.00 (46.03%) | Beli | 759.86 |
| RBC Capital | 02 Mar 2026 | 765.00 (21.03%) | Pegang | 790.81 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Apr 2026 | CNBC | Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free |
| Hasil Dividen (DY TTM) | 0.57% |
| Purata Hasil Dividen 1T | 0.46% |
| Nisbah Pembayaran | 2.24% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 20 May 2026 | - | 04 Jun 2026 | 0.94 Tunai |
| 20 Feb 2026 | - | 05 Mar 2026 | 0.94 Tunai |
| 20 Nov 2025 | - | 05 Dec 2025 | 0.88 Tunai |
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 Tunai |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 Tunai |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2026 | 1.88 | 2 | 0.30 |
| 2025 | 3.52 | 4 | 0.46 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |